Latest Ranibizumab Stories

Use of medications injected directly into the eye appears to be an increasingly common treatment for age-related macular degeneration in one region of Canada, but only a small proportion of ophthalmologists perform the procedure, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals.Age-related macular degeneration is the leading cause of blindness in Western nations, according to background information in the article. The development of...

TARRYTOWN, N.Y. and LEVERKUSEN, Germany, Feb. 18 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Bayer HealthCare AG today announced that VEGF Trap-Eye showed positive results in a Phase 2 study in patients with diabetic macular edema (DME). The primary endpoint of the study, a statistically significant improvement in visual acuity over 24 weeks compared to the standard of care in DME, macular laser therapy, was met. Visual acuity improvement was measured by...

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that both Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's aflibercept will earn Decision Resources' proprietary clinical gold standard status for wet age-related macular degeneration in 2013 and 2018. A unique future gold standard cannot be identified because neither thought-leader opinion nor available clinical...

Ophthalmology February highlightsThis month's Ophthalmology, the journal of the American Academy of Ophthalmology, includes results from a large Kaiser Permanente study of age-related macular degeneration (AMD) treatments, the first global report on retinal vein occlusion, and new recommendations to help elders with vision loss avoid falls.Kaiser Study Compares Effectiveness of Two AMD DrugsA Kaiser Permanente Southern California study compared two very similar medications"“ ranibizumab and...

ATLANTA, Dec. 23 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from the month 24 readout of the FAME Study. The FAME Study consists of two Phase 3 pivotal clinical trials (Trial A and Trial B) for the use of Iluvien in the treatment of diabetic macular edema (DME). The primary efficacy endpoint for the FAME...

NEW YORK, Dec. 15 /PRNewswire/ -- Ophthotech Corp., a biopharmaceutical company focused on developing novel ophthalmic therapies for both wet and dry age-related macular degeneration (AMD), announced today that it has closed a $30 million Series B financing round. The financing round was led by Clarus Ventures, which will be represented on Ophthotech's board of directors by Nicholas Galakatos, Ph.D., managing director of Clarus. Clarus is joined in the current round by existing investors SV...

VANCOUVER, Dec. 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland. EVEREST is the first multi-center, double-masked, indocyanine green angiography (ICG-A) -guided randomized controlled trial with an angiographic treatment outcome designed to assess the effect of Visudyne(R) (verteporfin photodynamic...

WALTHAM, Mass., Nov. 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of therapies to treat diabetic retinopathy, diabetic neuropathy and diabetic nephropathy will increase by more than 70 percent from $3.2 billion in 2008 to $5.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Diabetic Retinopathy,...

May have impact on use of new antiVEGF drugsScientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). This finding, published in the November 3, 2009 print edition of PNAS (Proceedings of the National Academy of Sciences), not...

Discovery may also have impact on the use of new drugs for wet macular degeneration BOSTON, Nov. 2 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). This finding, published in the November 3, 2009 print...